Navigation Links
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
Date:7/6/2009

Progression was evaluated using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale; the scores at study end were similar in both treatment groups (Lantus(R): 14.2%, NPH: 15.7%; 95% CI: -7.02, 3.06). As per protocol, the study aimed to achieve similar levels of glycemic control in both groups, in order to avoid introducing bias on the primary retinopathy end-point that could be related to differences in blood glucose control. Both groups had comparable HbA1c at study end (mean HbA1c improved from a baseline of 8.4% and 8.3% to 7.8% and 7.6% for all patients in the insuline glargine and NPH insulin groups respectively). NPH insulin was associated with a significantly greater incidence of severe hypoglycemia than was insulin glargine (11.1% vs 7.6% respectively, p=0.0439) and mean yearly rates of symptomatic hypoglycemia (7.08+/-16.49 vs 5.13+/-12.79, p=0.0017).

There was no observable trend for a difference in the incidence of serious adverse events including cancer, as well as adverse events leading to study withdrawal. The most common adverse events in the study were: upper respiratory tract infection (glargine 149 [29%], NPH 169 [33.6%]), peripheral edema (glargine 103 [20%], NPH 114 [22.7%]), and arthralgia (glargine 73 [14.2%], NPH 81 [16.1%]).

About the study

This long-term study was designed to further characterize the retinal safety profile of insulin glargine (glargine) and human neutral protamine Hagedorn insulin (NPH) in patients with type 2 diabetes mellitus.

This was an open-label, 5-year, randomized (1:1), multicentre, stratified, parallel-group study comparing patients treated with either twice-daily NPH (n=509) or once-daily basal glargine (n=515).

The main objective of this study was to compare the progression of diabetic retinopathy between treatment groups by analyzing the percentage of patients with greater than or equal to 3-st
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
2. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... COLUMBUS, Ohio , Aug. 19, 2014 ... Ohio medical device company, announced today that ... FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan ... Corporation is also the exclusive distributor for Karl Storz ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... ANGELES, Jan. 13, 2011 UBM Canon and ... webinar to its webcast series on The Fundamentals of ... on Advanced Assay Technologies and Development Methods ... experts in the industry.   (Logo:   ...
... 13, 2011 CareGiver remote instrument support has expanded ... Medical System, Inc. ("VMSI") is the leading innovator in ... 5 years of success on the SYMPHONY H&E slide ... BenchMark ULTRA, strengthening the integration of the SYMPHONY and ...
Cached Medicine Technology:Advanced Assay Technologies and Development Methods 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 3
(Date:8/20/2014)... Universities of Manchester and Auckland suggest that both major forms ... , The findings, published today in the FASEB Journal ... diabetes and type-2 diabetes are both caused by the formation ... , The results, based on 20 years, work in New ... slowed down and potentially reversed by medicines that stop amylin ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies ... for its annual fall conference, WEDI-Con 2014: The ... will take place at the HYATT Regency in ... diverse cross-section of payers, providers, government regulators, industry ...
(Date:8/20/2014)... August 20, 2014 If old age is ... cure for it. With extensive research on HGH and stem ... claims to have perfected the art of rubbing off decades ... new younger look with their revolutionary anti-aging hormone therapy and ... 21st century fountain of youth, the MD of MetroMD, Dr ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
Breaking Medicine News(10 mins):Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... 18 Codexis, Inc. today announced that Joseph Sarret, ... Corporate Development from his previous position as Vice President, ... Shaw, Ph.D., President and CEO. Dr. Sarret was ... joined Codexis in 2005 as Corporate Counsel and Director, ...
... Inc. (Nasdaq: MDVN ) today announced ... U.S. Food and Drug Administration (FDA) to begin ... novel androgen receptor antagonist, in patients with metastatic ... chemotherapy. The placebo-controlled, double-blind, multinational trial will ...
... smaller and more contained, study finds , , WEDNESDAY, March 18 ... reduce the risk of death by as much as half, ... information on 1,044 women who were seen at a medical ... had developed a second breast cancer -- 455 with cancer ...
... PHR Taps into Latino Market Underserved by ... Information Systems, Inc. (OTC Bulletin Board: FVRL), ... Inc. (collectively, "MMR") provides consumer-controlled Personal Health ... safe deposit box storage solutions ( www.myesafedepositbox.com ...
... 18 Kensey Nash Corporation (Nasdaq: KNSY ) ... stock repurchase. The new program allows the Company to ... and outstanding shares of Common Stock and has no scheduled ... its available cash. "Given our strong cash position and the ...
... they learned from elders who have been through economic ... simply being thankful can calm economic anxiety; other key ... optimism; what to avoid?: elders say don,t listen to ... released in conjunction with national conference Aging in America ...
Cached Medicine News:Health News:Codexis Names Sarret SVP, Corporate Development 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:When Breast Cancer Recurs, Finding Pre-Symptoms Is Key 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:New Survey: Top Lesson from Seniors About Economic Worries? Gratitude Trumps Fear 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: